Authors
Michaela Kotrova, Julia Alten, Andrea Biondi, Barbara Buldini, Mireia Camos, Gunnar Cario, Giovanni Cazzaniga, Sabina Chiaretti, Emmanuelle Clappier, Pritha Dasgupta, Daniela Drandi, Cornelia Eckert, Sarah Elitzur, Adele K Fielding, Eva Fronkova, Nicola Gökbuget, Michelle J Henderson, Abhirupa Kar, Seth E Karol, Irene Della Starza, Britta Kehden, Csongor Kiss, John Moppett, Bela Patel, Heike Pfeifer, Carmelo Rizzari, Josep-Maria Ribera, Susana Rives, Anke Schilhabel, Lewis B Silverman, Nicholas J Short, David T Teachey, Toby N Trahair, Vincent H J van der Velden, Kerry Wall, Jacques J M van Dongen, Jan Zuna, Nicolas Boissel, Martin Schrappe, Monika Brüggemann
Published in
Blood. Nov 10, 2026. Epub Nov 10, 2026.
Abstract
Measurable residual disease (MRD) assessment is central to risk stratification, response evaluation, and relapse detection in acute lymphoblastic leukemia (ALL). However, substantial global variability in its methodology and implementation persists. Differences in sampling strategies, detection methods, reporting thresholds, and interpretation criteria hinder cross-trial comparability and clinical standardization. To address this, an international expert panel representing major pediatric and adult study groups and reference laboratories developed consensus recommendations, using a structured current-practices survey followed by a multi-round Delphi process. Consensus was achieved on 38 of 41 statements. Recommendations span three domains: pre-analytical requirements, technical and nomenclature standards, and MRD-based remission and relapse definitions. Bone marrow was endorsed as the reference specimen for MRD assessment, and MRD was prioritized over cytomorphology in cases of discordance. Principles for risk- and actionability-guided late MRD monitoring, confirmation of MRD reappearance, and MRD-informed relapse assessment were also defined. Among the key technical consensus statements, a standardized MRD assay nomenclature was adopted. Areas without consensus-namely, anticoagulant choice for PCR-based MRD, interpretation of isolated BCR::ABL1 reconversion, and the exclusive use of MRD to define remission-highlight ongoing biological and clinical complexity. This guideline, applicable across all ages, provides a practical framework to standardize MRD assessment in ALL and support MRD-guided clinical decision-making.
PMID:
43008231
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 28
- Comments 0